Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Documented diagnosis of malignant solid tumor with measurable disease

• Life expectancy of at least 12 weeks

• ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2

Exclusion Criteria:

• Recent major surgery, radiation therapy or anti-cancer treatment

• History of any other prior malignancy within the last 5 years